Lithium Versus Lamotrigine in Bipolar Disorder, Type II

Launched by MENTAL HEALTH SERVICES IN THE CAPITAL REGION, DENMARK · Dec 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, lithium and lamotrigine, on people with Bipolar II Disorder. The goal is to see which medication better helps stabilize mood and improve overall health in patients over a six-month period. The trial is currently looking for participants aged 18 to 65 who speak Danish and have a confirmed diagnosis of Bipolar II Disorder.

If you choose to participate, you will be randomly assigned to receive either lithium or lamotrigine. Your progress will be monitored closely throughout the study. However, there are some important criteria for joining, such as not having had serious side effects from these medications in the past or having certain health conditions like severe kidney or heart issues. This study aims to provide valuable information that could help improve treatment options for people with Bipolar II Disorder in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Bipolar disorder, type II with diagnosis confirmed by SCAN interview
• • Age 18-65 years
• • Habile (i.e., able to give informed consent)
• • Speaks Danish
• Exclusion Criteria:
• • Past non-response or intolerance to lamotrigine or lithium with \> 6 weeks treatment at an adequate dosage
• • Currently taking mood stabilizers at enrollment in CADIC
• • Severe chronic kidney disease
• • Severe cardiac insufficiency
• • Brugadas syndrome
• • Severe hypothyroidism despite treatment
• • Women who are pregnant, breastfeeding or planning pregnancy in near future.